PMID- 31819412
OWN - NLM
STAT- MEDLINE
DCOM- 20200221
LR  - 20220411
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Print)
IS  - 1176-9114 (Linking)
VI  - 14
DP  - 2019
TI  - Comparative Effect Of Curcumin Versus Liposomal Curcumin On Systemic 
      Pro-Inflammatory Cytokines Profile, MCP-1 And RANTES In Experimental Diabetes 
      Mellitus.
PG  - 8961-8972
LID - 10.2147/IJN.S226790 [doi]
AB  - PURPOSE: Anti-inflammatory proprieties of curcumin were proved to be useful in 
      various diseases, including diabetes mellitus. The aim of this study was to 
      assess the anti-inflammatory comparative effect of curcumin solution with 
      liposomal curcumin formula, regarding the improvement of serum levels of TNF-alpha 
      (tumor necrosis factor-alpha), IL-6 (interleukin), IL-1alpha, IL-1beta, MCP-1 (monocyte 
      chemoattractant protein-1) and RANTES in experimental diabetes, induced by 
      streptozotocin (STZ), in rats. MATERIALS AND METHODS: Six groups of 7 rats were 
      investigated regarding the effect of i.p. (intraperitoneal) administration of two 
      concentrations of curcumin solution (CC1 and CC2) and two concentrations of 
      liposomal curcumin (LCC1 and LCC2): group 1 - control group with i.p. 
      administration of 1 mL saline solution, group 2 - i.p. STZ administration 
      (60mg/kg bw, bw=body weight), group 3 - STZ+CC1 administration, group 4 - STZ+CC2 
      administration, group 5 - STZ+ LCC1 administration and group 6 - STZ+ LCC2 
      administration. The concentrations of curcumin formulas were 1 mg/0.1 kg bw for 
      CC1 and LCC1 and 2 mg/0.1 kg bw for CC2 and LCC2, respectively. Serum levels of 
      C-peptide (as an indicator of pancreatic function) and TNF-alpha, IL-6, IL-1alpha, IL-1beta, 
      MCP-1, and RANTES (as biomarkers for systemic inflammation) were assessed for 
      each group. RESULTS: The plasma level of C-peptide showed significant 
      improvements when LCC was administrated, with better results for LCC2 when 
      compared to LCC1 (P<0.003). LCC2 pretreatment proved to be more efficient in 
      reducing the level of TNF-alpha (P<0.003) and RANTES (P<0.003) than CC2 pretreatment. 
      Upon comparing LCC2 with LCC1 formulas, the differences were significant for 
      TNF-alpha (P=0.004), IL-1beta (P=0.022), and RANTES (P=0.003) levels. CONCLUSION: 
      Liposomal curcumin in a dose of 2 mg/0.1 kg bw proved to have an optimum 
      therapeutic effect as a pretreatment in DM induced by STZ. This result can 
      constitute a base for clinical studies for curcumin efficiency as adjuvant 
      therapy in type 1 DM.
CI  - (c) 2019 Bulboaca et al.
FAU - Bulboaca, Adriana Elena
AU  - Bulboaca AE
AUID- ORCID: 0000-0001-7748-382X
AD  - Pathophysiology Department, Iuliu Hatieganu University of Medicine and Pharmacy 
      Cluj-Napoca, Cluj-Napoca, Romania.
FAU - Boarescu, Paul Mihai
AU  - Boarescu PM
AD  - Pathophysiology Department, Iuliu Hatieganu University of Medicine and Pharmacy 
      Cluj-Napoca, Cluj-Napoca, Romania.
FAU - Bolboaca, Sorana D
AU  - Bolboaca SD
AUID- ORCID: 0000-0002-2342-4311
AD  - Department of Medical Informatics and Biostatistics, Iuliu Hatieganu University 
      of Medicine And Pharmacy, Cluj-Napoca, Romania.
FAU - Blidaru, Mihai
AU  - Blidaru M
AD  - Pathophysiology Department, Iuliu Hatieganu University of Medicine and Pharmacy 
      Cluj-Napoca, Cluj-Napoca, Romania.
FAU - Festila, Dana
AU  - Festila D
AD  - Department of Maxillofacial Surgery and Radiology, Iuliu Hatieganu University of 
      Medicine and Pharmacy, Cluj-Napoca, Romania.
FAU - Dogaru, Gabriela
AU  - Dogaru G
AD  - Department of Physical Medicine and Rehabilitation, Iuliu Hatieganu University of 
      Medicine and Pharmacy, Cluj-Napoca, Romania.
FAU - Nicula, Cristina Ariadna
AU  - Nicula CA
AUID- ORCID: 0000-0002-3222-6448
AD  - Department of Ophthalmology, Iuliu Hatieganu University of Medicine and Pharmacy 
      Cluj-Napoca, Cluj-Napoca, Romania.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20191118
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Liposomes)
RN  - 5W494URQ81 (Streptozocin)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Biomarkers/metabolism
MH  - Chemokine CCL2/*metabolism
MH  - Chemokine CCL5/*metabolism
MH  - Curcumin/administration & dosage/*therapeutic use
MH  - Cytokines/*metabolism
MH  - Diabetes Mellitus, Experimental/*drug therapy/*metabolism
MH  - Inflammation/*drug therapy
MH  - Inflammation Mediators/*metabolism
MH  - Liposomes
MH  - Male
MH  - Rats
MH  - Streptozocin
PMC - PMC6873975
OTO - NOTNLM
OT  - curcumin
OT  - cytokine
OT  - diabetes mellitus
OT  - inflammation
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/12/11 06:00
MHDA- 2020/02/23 06:00
PMCR- 2019/11/18
CRDT- 2019/12/11 06:00
PHST- 2019/08/11 00:00 [received]
PHST- 2019/10/25 00:00 [accepted]
PHST- 2019/12/11 06:00 [entrez]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/11/18 00:00 [pmc-release]
AID - 226790 [pii]
AID - 10.2147/IJN.S226790 [doi]
PST - epublish
SO  - Int J Nanomedicine. 2019 Nov 18;14:8961-8972. doi: 10.2147/IJN.S226790. 
      eCollection 2019.